Craig-Hallum Sticks to Its Hold Rating for Avid Bioservices (CDMO)
Stephens Downgrades Avid Bioservices to Equalweight, Price Target Is $12.50
Avid Bioservices Downgraded to Hold From Buy at Craig-Hallum
Avid Bioservices Price Target Raised to $12.50/Share From $12.00 by RBC Capital
Avid Bioservices Analyst Ratings
Avid Bioservices Analyst Ratings
RBC Capital Sticks to Its Buy Rating for Avid Bioservices (CDMO)
Craig-Hallum Releases a Buy Rating on Avid Bioservices (CDMO)
Craig-Hallum Reaffirms Their Buy Rating on Avid Bioservices (CDMO)
Avid Bioservices Analyst Ratings
RBC Capital Sticks to Its Buy Rating for Avid Bioservices (CDMO)
Avid Bioservices (CDMO) Receives a Buy From Craig-Hallum
Craig-Hallum Sticks to Their Buy Rating for Avid Bioservices (CDMO)
Avid Bioservices Analyst Ratings
Analysts' Opinions Are Mixed on These Healthcare Stocks: Harmony Biosciences Holdings (HRMY), Decibel Cannabis Company (OtherDBCCF) and Avid Bioservices (CDMO)
Analysts Offer Insights on Healthcare Companies: AIM ImmunoTech (AIM) and Avid Bioservices (CDMO)
Craig-Hallum Remains a Buy on Avid Bioservices (CDMO)
Analysts' Top Healthcare Picks: Avid Bioservices (CDMO), LifeMD (LFMD)
Craig-Hallum Remains a Buy on Avid Bioservices (CDMO)
Avid Bioservices Analyst Ratings
No Data